Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharma Q2 revenues climb
For the second quarter of 2011, the company has posted net income of $56.36m, or $0.17 per diluted share, compared to $33.97m, or $0.21 per diluted share, for
For the second quarter of 2011, the company has posted net income of $56.36m, or $0.17 per diluted share, compared to $33.97m, or $0.21 per diluted share, for
The multicenter, open-label, randomized study was designed to assess the safety and tolerability of hGH-CTP in growth hormone deficient adults. The data demonstrated that a single weekly injection
The results of the trial suggested that MDV3100 inhibits proliferation of breast cancer cells. The results demonstrated that androgens dihydrotestosterone (DHT) or R1881 treatment had a proliferative effect
The company intends to conduct the research work in cooperation with the University of British Columbia and the BC Cancer Agency. The data from preclinical trials showed anti-cancer
LabPartner is a provider of lab equipment, reagents, consumables and services for research and development. LabPartner delivers products and integrated services, with a focus on chemical distribution to
Roche‘s Boulder plant, engaged in the production of therapeutic peptide compounds, is equipped with large scale synthetic manufacturing technologies. The agreement allows ICIG to take over the technical
As per the terms of the agreement, GSK is responsible to pay up to EUR5.5m to MolMed in revenues for a term of two-year. Developed by the San
For the second quarter of 2011, the company has posted net loss of $51.51m, or $0.45 loss per diluted share, compared to $8.32m, or $0.08 loss per diluted
For the second quarter of 2011, the company has posted net loss of $17.3m, or $0.19 loss per diluted share, compared to $4.06m, or $0.05 loss per diluted
The companies’ decision was supported by the reevaluation of pramlintide/metreleptin program which had been in Phase 2 development as a twice-a-day injection formulation as a treatment for obesity.